GlassScriptPhysician profile
Victor Wei-Ming Yang
NPI 1023004470
$45,872.84
in general payments reported to CMS, 2019-2025
37 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,055 · 2021: $11K · 2022: $8,759 · 2023: $8,665 · 2024: $1,160 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,540 · Food and Beverage: $3,692 · Travel and Lodging: $867 · Education: $36.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,540.00 |
| Food and Beverage | $3,691.90 |
| Travel and Lodging | $866.75 |
| Education | $36.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $37,268.68 | 2019-2025 | Vemlidy |
| Abbvie INC. | $1,597.54 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,558.55 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,063.57 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $738.90 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.47 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $409.84 | 2021-2023 | |
| Madrigal Pharmaceuticals | $365.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $324.48 | 2019-2023 | Suflave, Sutab |
| Vivus LLC | $262.59 | 2023-2024 | Qsymia, Pancreaze |
| Redhill Biopharma INC. | $254.61 | 2020-2022 | |
| Romark Laboratories, Lc | $153.14 | 2019 | |
| Lilly USA, LLC | $152.58 | 2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Pfizer INC. | $114.74 | 2023-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $91.45 | 2020 | |
| Intercept Pharmaceuticals, INC. | $79.67 | 2019-2024 | |
| Ardelyx, INC. | $78.24 | 2023-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $77.12 | 2025 | Givlaari |
| Ironwood Pharmaceuticals, INC | $72.09 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $72.06 | 2024-2025 | Voquezna |
| Ucb, INC. | $58.87 | 2019-2023 | Cimzia |
| Philips North America LLC | $51.62 | 2021-2022 | |
| Allergan, INC. | $46.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.12 | 2019 | |
| Shionogi INC | $42.88 | 2019 | |
| Nestle Healthcare Nutrition INC. | $40.19 | 2021 | |
| Echosens North America, INC. | $34.63 | 2025 | Fibroscan |
| Aimmune Therapeutics, INC. | $26.54 | 2025 | Zenpep |
| Biocon Biologics INC | $24.77 | 2025 | Yesintek |
| Genzyme Corporation | $24.11 | 2022 | |
| Novo Nordisk INC | $21.97 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $21.52 | 2023 | Clenpiq |
| Celltrion USA INC. | $17.32 | 2024 | Zymfentra |
| Qol Medical, LLC | $16.12 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.